Clinical trials: Allergen Immunotherapy
Allergy
A Trial of the ALK Grass Tablet in Subjects With Hayfever
This trial is performed to assess the efficacy and safety of the ALK Grass tablet for treatment of grass pollen induced rhinoconjunctivitis (hayfever).
- Trial name
- NCT00227279
- Testing
- ALK Grass tablet
- Where
- Denmark
- Volunteers
- 634 people
- Sponsor
- ALK-Abelló A/S
Rhinoconjunctivitis
Evaluation of Safety and Efficacy of Specific Immunotherapy With Recombinant Major Allergens of Timothy Grass Pollen Adsorbed Onto Aluminium-hydroxide in Patients With IgE-mediated Allergic Rhinoconjunctivitis +/- Controlled Asthma
Efficacy and Safety from a high-dosed subcutaneous recombinant preparation
- Trial name
- AMETHYST (NCT00671268)
- Testing
- AL0704rP
- Where
- Germany
- Volunteers
- 256 people
- Sponsor
- Allergopharma GmbH & Co. KG
Allergy to Grass Pollen
Biological Standardization of Poa Pratensis Allergen Extract
The objective of this study is to determine the biologic activity of a Poa pratensis allergen extract in histamine equivalent prick (HEP) units, in order to be used as in-house reference preparation (IHRP).
- Trial name
- NCT01430117
- Testing
- Four different concentrations of Poa pratensis allergen extract, positive control and negative control
- Where
- 2 sites in Spain
- Volunteers
- 31 people
- Sponsor
- Laboratorios Leti, S.L.
Rhinitis or Rhinoconjunctivitis With or Without Asthma Induced by Hypersensitivity to Olea Europea Pollen
Subcutaneous Immunotherapy Treatment for Patients With Hypersensitivity to Olea Europaea Pollen
The objective of this trial is to assess the clinical efficacy of a modified allergen extract of Olea europaea pollen in the treatment of patients affected by allergic rhinitis/rhinoconjunctivitis (with or without episodic…
- Trial name
- OLEA (NCT00831025)
- Testing
- Immunotherapy with modified extract of Olea europaea pollen
- Where
- 7 sites in Spain
- Volunteers
- 158 people
- Sponsor
- Laboratorios Leti, S.L.
Allergic Rhinitis Due to Grass Pollens
Study of Efficacy and Safety of 300 IR Sublingual Immunotherapy (SLIT) Tablets in Adult Patients With Allergic Grass Pollen Rhinoconjunctivitis
The purpose of the study is to assess the efficacy and safety of 300 IR sublingual tablet of grass pollen allergen extract compared to placebo in adult patient with allergic rhinoconjunctivitis.
- Trial name
- NCT00955825
- Testing
- 300 IR
- Where
- 19 sites in United States
- Volunteers
- 473 people
- Sponsor
- Stallergenes Greer
Food Allergy
Open-label Extension Study of ADP101
This is an open-label, safety extension study for participants who participated in the Harmony study (protocol ADP101-MA-01).
- Trial name
- NCT05243719
- Testing
- ADP101
- Where
- 14 sites in United States
- Volunteers
- 45 people
- Sponsor
- Alladapt Immunotherapeutics, Inc.
Allergic Reactions
Study Evaluating the Safety and Efficacy of Neffy or Intramuscular Adrenalin in Patients With Allergic Reactions After Oral Food Challenge or Allergen Immunotherapy
The study is to assess the safety of neffy or IM Adrenalin in patients who are experiencing allergic reactions after an OFC, allergen Immunotherapy (AIT), or other allergy challenge that may require epinephrine intervention.
- Trial name
- NCT06834165
- Testing
- Neffy, Adrenaline
- Where
- 6 sites in United States
- Volunteers
- 600 people
- Sponsor
- ARS Pharmaceuticals, Inc.
Allergy to Grass Pollen (Secale Cereale)
Biological Standardization of Secale Cereale Allergen Extract
The objective of this study is to determine the biologic activity of a Secale cereale allergen extract in histamine equivalent prick (HEP) units, in order to be used as in-house reference preparation (IHRP).
- Trial name
- NCT01408238
- Testing
- Four different concentrations of Secale cereale allergen extract, positive control and negative control
- Where
- 2 sites in Spain
- Volunteers
- 35 people
- Sponsor
- Laboratorios Leti, S.L.
House Dust Mite Allergy, Rhinoconjunctivitis
ToleroMune House Dust Mite Follow on Study
House Dust Mites (HDM) are arachnids that infest bedding, carpet, upholstered furniture and fabric. Like many other allergens, exposure to HDM allergens in sensitised patients is associated with poorer lung function, greater…
- Trial name
- NCT01923792
- Volunteers
- 105 people
- Sponsor
- Circassia Limited
Allergic Rhinitis
Evaluation of Efficacy and Safety of Specific Immunotherapy With Modified Allergen Extracts of House Dust Mites
The objective of this study is to evaluate the efficacy and safety of specific subcutaneous immunotherapy with modified allergen extracts.
- Trial name
- NCT01013116
- Testing
- modified allergen extract of house dust mites
- Where
- Spain
- Volunteers
- 120 people
- Sponsor
- Roxall Medizin
Peanut Allergy
Real-World AR101 Market-Supporting Experience Study in Peanut-Allergic Children (RAMSES)
This is a multicenter, randomized, double-blind, placebo-controlled safety study of AR101 using the characterized oral desensitization immunotherapy (CODIT™) regimen in peanut-allergic children.
- Trial name
- RAMSES (NCT03126227)
- Testing
- AR101
- Where
- 67 sites in United States, Canada
- Volunteers
- 506 people
- Sponsor
- Aimmune Therapeutics, Inc.
Rhinoconjunctivitis
Multicenter Trial of Immunotherapy With House Dust Mite Allergoid
Multicenter Immunotherapy House Dust Mite Allergoid
- Trial name
- ACRI (NCT00540631)
- Testing
- specific immunotherapy with Acaroid, subcutaneously, Up-titration till strength B 0.6 mL (6000 TU)
- Where
- Germany
- Volunteers
- 108 people
- Sponsor
- Allergopharma GmbH & Co. KG
Peanut Allergy
ARTEMIS Peanut Allergy In Children
The purpose of this study is to demonstrate the efficacy and safety of AR101 through oral immunotherapy (OIT) in peanut-allergic children.
- Trial name
- ARTEMIS (NCT03201003)
- Testing
- AR101 powder provided in capsules & sachets
- Where
- 18 sites in France, Germany and 5 more
- Volunteers
- 175 people
- Sponsor
- Aimmune Therapeutics, Inc.
Peanut Allergy
Longer-term Study of AR101 in Subjects Who Participated in a Prior AR101 Study (ARC008)
The purpose of this study is to assess AR101's safety, tolerability and efficacy over an extended dosing period.
- Trial name
- NCT03292484
- Testing
- AR101
- Where
- 93 sites in United States, Canada and 8 more
- Volunteers
- 911 people
- Sponsor
- Aimmune Therapeutics, Inc.
Allergic Rhinitis Due to Dust Mite
Safety and Efficacy Study of Sublingual Immunotherapy (SLIT) to Treat House Dust Mite Allergic Rhinitis in Adolescents and Children
The purpose of this study is to assess the efficacy of one dose of sublingual immunotherapy (SLIT) administered to children and adolescents as allergen-based tablets once daily over a period of 24 months over 3 years compared to…
- Trial name
- NCT01199133
- Testing
- 300 IR house dust mites allergen extract tablet
- Volunteers
- 471 people
- Sponsor
- Stallergenes Greer
Cat Allergy
Cat-PAD Exposure Chamber Study
Cat allergy is an increasingly prevalent condition, affecting 10-15% of patients with allergic rhinoconjunctivitis and/or asthma.
- Trial name
- NCT01033344
- Testing
- Cat-PAD
- Where
- Canada
- Volunteers
- 210 people
- Sponsor
- Circassia Limited
Rhinitis, Conjunctivitis
Study on Pharmacodynamic Parameter and Tolerability With Subcutaneous Immunotherapy in Grass Pollen Allergic Patients
The aim of this study is to test the pharmacodynamic equivalence with respect to IgE-blocking factor and to compare the tolerability of two different updosing schedules with ALK-Flex SQ
- Conditions
- Rhinitis, Conjunctivitis, Asthma
- Trial name
- NCT00857779
- Testing
- subcutaneous immunotherapy
- Where
- Germany
- Volunteers
- 473 people
- Sponsor
- ALK-Abelló A/S
Peanut Allergy
PALISADE Follow-on Study (ARC004)
The purpose of this study is to demonstrate the safety, tolerability, and efficacy of AR101 through oral immunotherapy (OIT) in peanut-allergic children and adults who have completed the ARC003 study.
- Trial name
- NCT02993107
- Testing
- AR101
- Where
- 65 sites in United States, Canada and 7 more
- Volunteers
- 388 people
- Sponsor
- Aimmune Therapeutics, Inc.
Rhinitis, Allergic, Rhinoconjunctivitis
Study to Evaluate the Efficacy and Safety of "Allergovac Poliplus" in Polysensitized Patients With Allergic Rhinitis/Rhinoconjunctivitis, With or Without Asthma
This is an observational prospective multicenter clinical study, to evaluate the efficacy and safety of the treatment with Allergovac Poliplus subcutaneous immunotherapy (SCIT) with a mixture of 2 allergenic extracts (pollens or…
- Trial name
- ARES (NCT03821077)
- Testing
- Allergen Immunotherapy (AIT)
- Where
- 10 sites in Spain
- Volunteers
- 122 people
- Sponsor
- Roxall Medicina España S.A
Peanut Allergy
Peanut Oral Immunotherapy Study of Early Intervention for Desensitization
The purpose of this study is to determine the efficacy and safety of AR101 in peanut-allergic children aged 1 to < 4 years.
- Trial name
- POSEIDON (NCT03736447)
- Testing
- AR101 powder provided in capsules & sachets
- Where
- 23 sites in United States, France and 2 more
- Volunteers
- 146 people
- Sponsor
- Aimmune Therapeutics, Inc.